Syndax unveils SNDX-4321 EGFR inhibitor and SNDX-62122 for myelofibrosis at R&D event
Syndax Pharmaceuticals held an R&D event on July 14, 2026, and disclosed two pipeline additions: SNDX-4321, an externally licensed EGFR inhibitor for non-small cell lung cancer, and SNDX-62122, a next-generation menin inhibitor selected for myelofibrosis. The filing furnishes the press release and presentation but gives no new financial results, and it sets out development timelines, including a Phase 2 axatilimab trial in IPF with topline data expected in 4Q26.
Key points
- SNDX-4321: IND submission expected by end of 2026 and Phase 1 trial in EGFR-mutated NSCLC planned for 2027; Syndax holds an exclusive worldwide license.
- SNDX-62122 is the first candidate from Syndax's wholly owned next-generation menin inhibitor library; a revumenib Phase 1/2 proof-of-principle trial in myelofibrosis is expected to start in 4Q26.
- Phase 2 trial of axatilimab in IPF remains on track for topline data in 4Q26.
- Presentation states Revuforj and Niktimvo were each annualizing at about $200 million as of 1Q26.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.